Pretax income is the income that a company earns before paying income taxes. SCYNEXIS's pretax income for the
three
months ended in Dec. 2023 was $-19.4 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $67.2 Mil.
SCYNEXIS's pretax margin was -335.48%.
During the past 12 years, SCYNEXIS's highest Pretax Margin was 47.94%. The lowest was -44388.43%. And the median was -7472.37%.
SCYNEXIS Pre-Tax Income Historical Data
The historical data trend for SCYNEXIS's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SCYNEXIS's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Pre-Tax Income falls into.
SCYNEXIS Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
SCYNEXIS's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $67.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (NAS:SCYX) Pre-Tax Income Explanation
SCYNEXIS's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 12 years, SCYNEXIS's highest Pretax Margin was 47.94%. The lowest was -44388.43%. And the median was -7472.37%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 